美国有线新闻 CNN 民调显示45%的美国人不会接种新冠疫苗（在线收听）

We told you earlier this week how Pfizer, an American pharmaceutical company, says it's seen some promising early results from a coronavirus vaccine it's working on. It's not the only company racing to do this. Since the pandemic began, researchers worldwide have been trying to learn all they can about the disease and develop methods and medicines to stop it. Russia's government says it's approved two vaccines intended to protect people from COVID-19, though critics say the shots have not undergone the same amount of testing they would have in the United States.

本周早些时候，我们报道了美国制药公司辉瑞的相关消息，该公司称其从目前研究的冠状病毒疫苗中看到了一些有希望的早期结果。辉瑞并不是唯一一家加紧研制疫苗的公司。自从新冠肺炎疫情爆发以来，世界各地的研究人员一直在努力了解有关这种疾病的一切知识，并研发预防方法和药物。俄罗斯政府表示，他们已经批准了两种疫苗，旨在保护人们免受新冠肺炎的感染，尽管批评人士表示，这些疫苗没有像在美国那样进行同等程度的测试。

Still, the fact that several organizations have even gotten close is remarkable because it usually takes several years and often 10 or more for a vaccine to go from development to the doctor's office. Even when a vaccine is approved in the U.S., a CNN poll conducted last month indicated that 45 percent of Americans would not try to get vaccinated if a vaccine were widely available at low cost. 51 percent of Americans said they would try to get vaccinated but that percentage had decreased since May. So that's one obstacle for Pfizer and other vaccine advocates along with the basic logistics of distributing the shot around the world.

尽管如此，值得注意的是，多个机构的研究已经接近目标，因为疫苗从研发到分发到医生手中通常需要数年，甚至是10年以上的时间。美国有线电视新闻网（简称CNN）上个月进行的一项民意调查显示，即使疫苗在美国获得批准且能以较低成本广泛应用，仍有45%的美国人不会尝试接种疫苗。51%的美国人表示会尝试接种疫苗，但这一比例自5月份以来有所下降。因此，这是辉瑞和其他疫苗倡导者面临的一个障碍，此外，还有向全世界分发疫苗的物流问题。